Pharmacosmos and G1 Therapeutics Complete Key Acquisition Deal

Pharmacosmos A/S and G1 Therapeutics Complete Strategic Acquisition

- Transaction Will Maximize the Access and Uptake of COSELA (trilaciclib), the First and Only Proactive Multilineage Myeloprotection Agent -

- G1 Stockholders to Receive U.S. $7.15 Per Share in Cash -

Pharmacosmos A/S, a leader in innovative treatments for patients dealing with iron deficiency, has made a significant stride in its growth strategy by successfully acquiring G1 Therapeutics, Inc. This commercial-stage oncology company is dedicated to advancing new therapies that greatly improve the quality of life for cancer patients. The completed tender offer reflects a price of U.S. $7.15 per share for G1 Therapeutics stock, valuing the total transaction at around $405 million.

Tobias S Christensen, CEO and President of Pharmacosmos A/S, expressed enthusiasm about the acquisition, highlighting how it aligns with the company's strategy to enhance its product offerings. With the introduction of COSELA, a first-in-class treatment for patients with small cell lung cancer, Pharmacosmos aims to spread its benefits to a broader patient demographic, particularly focusing on the U.S. market, where it is currently approved, as well as on international registration efforts including the UK and EU.

Details of the Acquisition Process

The tender offer initiated on August 20, 2024, with an expiration set for September 17, 2024. The result of the tender offer showed that 39,486,447 shares of G1 Therapeutics common stock were tendered, signifying approximately 74.64% of the total outstanding shares. This satisfied the minimum tender conditions laid out during the offer. Subsequent to the conclusion of the tender offer, Genesis Merger Sub, Inc., a wholly-owned subsidiary of Pharmacosmos, accepted all validly tendered shares for payment.

As a result of the tender offer, G1 Therapeutics has merged with the purchasing entity, maintaining G1 Therapeutics as the surviving company and a fully owned subsidiary of Pharmacosmos Therapeutics Inc. In this merger process, all non-tendered shares were converted to the cash amount of the offer price, marking a significant transition as G1 Therapeutics stock ceases trading on NASDAQ.

The Future of COSELA and Cancer Patient Support

Jack Bailey, CEO of G1 Therapeutics, reflected on the journey leading to this acquisition since the inception of G1 in 2008. The efforts culminated in the development of COSELA, the first therapy designed to proactively provide multilineage myeloprotection to patients undergoing chemotherapy for extensive-stage small cell lung cancer. The closure of this transaction is a promising opportunity for both organizations as they join forces to expand the reach of COSELA to meet the needs of more cancer patients.

Advisors Involved in the Transaction

Pursuing this strategic acquisition, Pharmacosmos engaged MTS Health Partners, L.P. as their exclusive financial advisor, while Arnold & Porter Kaye Scholer LLP provided legal counsel. On the other side, G1 Therapeutics was advised by Centerview Partners LLC for financial guidance and benefitted from legal representation by Ropes & Gray LLP as well as Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

Importance of COSELA and Safety Information

COSELA (trilaciclib) is a crucial treatment option designed to reduce the occurrence of chemotherapy-induced myelosuppression in adult patients receiving specific chemotherapy regimens. It is essential for patients to be aware that COSELA is contraindicated in cases of serious hypersensitivity reactions to trilaciclib. It is important to observe the warnings associated with COSELA, which include injection-site reactions, acute hypersensitivity reactions, and more. Common adverse reactions noted in patients include fatigue, hypocalcemia, and pneumonia.

About Pharmacosmos A/S and G1 Therapeutics

Founded in 1965 and based in Holbaek, Denmark, Pharmacosmos specializes in carbohydrate chemistry and is recognized as a pioneering force in developing treatments for iron deficiency and related anemia. The company has expanded its market presence across multiple countries and emphasizes a strong commitment to research and development.

G1 Therapeutics, a biopharmaceutical company headquartered in Research Triangle Park, N.C., is on a mission to innovate therapeutic advances for cancer treatment. Their flagship product, COSELA, reflects their dedication to supporting patients affected by cancer. As both companies integrate, their focus will be directed toward enhancing cancer care accessibility and patient outcomes.

For inquiries regarding Pharmacosmos A/S, contact:

Christian Lundquist Madsen
VP Global Marketing & Communication
+45 5948 5959
clm@pharmacosmos.com

For G1 Therapeutics, reach out to:

Will Roberts
Communications Officer
Vice President, Investor Relations and Corporate Communications
(919) 907-1944
wroberts@g1therapeutics.com

Frequently Asked Questions

What is the primary benefit of the Pharmacosmos acquisition of G1 Therapeutics?

The acquisition aims to enhance patient access to COSELA, a key treatment for small cell lung cancer, improving outcomes for cancer patients.

How does COSELA work?

COSELA proactively reduces the incidence of chemotherapy-induced myelosuppression, providing critical support to patients during chemotherapy treatment.

What are the most common side effects associated with COSELA?

Common side effects include fatigue, hypocalcemia, and headache, highlighting the importance of patient monitoring during treatment.

When did the acquisition take place?

The acquisition was completed following the tender offer that expired on September 17, 2024.

Who were the advisors involved in the acquisition?

Financial and legal advisors included MTS Health Partners, Centerview Partners, Arnold & Porter Kaye Scholer LLP, and others assisting both companies in the merger process.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.